Technology
Built to defeat
viral mutations
Virucidal Therapeutics Platform
A virucidal therapeutic platform based on validated rHDL production technology, designed to target enveloped viruses such as COVID-19, influenza, and mpox.
Virucidal rHDL(VH)
Virucidal rHDL—derived from virus + -cide (“to kill”)—is an rHDL conjugated with a viral receptor. VH induces intracellular viruses to self-destruct through their own mechanisms once they enter the cell.
Advantages
Resistance and mutation-resilient therapy
By exploiting the viral infection cycle, the virucidal mechanism carries a low risk of resistance.
Superior safety
Produced with human-derived components such as rHDL, making it highly safe for the body.
Virucidal platform technology
By modifying viral receptors, it can be designed to target a wide range of enveloped viruses.
MND-M8
In the viral receptor region of VH, sialic acid—known to recognize influenza viruses—was attached.
Compared to the natural infection mechanism, it prevents viral genetic material from entering the nucleus by exploiting the virus’s tendency to bind to sialic acid and induce membrane fusion. In addition, it does not exhibit cytotoxicity that randomly attacks other cells in the body, making it highly safe.
R&D Achievements
Discover the intellectual property activities we are pursuing around virucidal platform.
Filed
PCT
Sep 17, 2020
Status
Tag protein for increasing water solubility and heat stability of target protein, and fusion protein comprising same
Filed
PCT
Sep 21, 2020
Status
Nano-perforator having improved anti-viral activity
Filed
KR
Jan 27, 2022
Status
Antibody-conjugated lipid nanoparticle
Filed
CN
Mar 22, 2022
Status
Nanoperforator with enhanced antiviral activity
Filed
IN
Mar 23, 2022
Status
항-바이러스 활성이 향상된 나노 천공자
Filed
US
Mar 23, 2022
Status
Nano-perforator having improved anti-viral activity
Filed
EU
Mar 24, 2022
Status
Nano-perforator having improved anti-viral activity
Filed
PCT
Apr 17, 2022
Status
Pharmaceutical composition for preventing or treating virus infections, comprising polymer nanodiscs
Filed
KR
Jul 5, 2022
Status
Immunodisk for Use in Antiviral Treatment
Filed
PCT
Feb 9, 2023
Status
Nanodisc comprising angiotensin converting enzyme 2
Abstract
Filed
PCT
Feb 9, 2023
Status
Nanodisc comprising angiotensin converting enzyme 2 and antiviral use thereof
Filed
PCT
Jul 4, 2023
Status
Nanodisc comprising membrane scaffold protein having fc region of antibody fused thereto
Filed
EU
Oct 9, 2023
Status
Pharmaceutical composition for preventing or treating virus infections, comprising polymer nanodiscs
Filed
CN
Oct 13, 2023
Status
Pharmaceutical composition for preventing or treating viral infections comprising polymeric nanodisks
Filed
US
Oct 19, 2023
Status
Pharmaceutical composition for preventing or treating virus infections, comprising polymer nanodiscs
Filed
PCT
Jan 29, 2024
Status
Nanodiscs comprising fab fragments and fc fragments of antibody and antiviral use thereof
Filed
US
Mar 8, 2024
Status
Viral receptor bound with sialic acid compounds
Filed
KR
Mar 19, 2024
Status
Nanodisc comprising angiotensin converting enzyme 2 fused with Fc fragment and use thereof
Filed
KR
Jun 25, 2024
Status
Nanodisc containing membrane scaffold protein fused with angiotensin converting enzyme 2 and and its antiviral use therof
Filed
US
Aug 20, 2024
Status
Nanodisc comprising angiotensin converting enzyme 2
Filed
PCT
Oct 3, 2024
Status
Nanodisc comprising angiotensin-converting enzyme 2 and fc fragment, and use thereof
Filed
PCT
Oct 3, 2024
Status
Nanodisc using dimer bonding
Filed
KR
Oct 24, 2024
Status
A pharmaceutical composition for the prevention or treatment of idiopathic pulmonary fibrosis comprising sACE2 nanodiscs
Filed
PCT
Jan 2, 2025
Status
Nanodisc comprising virus receptor and fc fragment, and antiviral use thereof
10-1455909
KR
Oct 22, 2014
Status
pH-responsive high density lipoprotein-like particle conjugate
10-1536037
KR
Jul 6, 2015
Status
Antibody-drug conjugate comprising apolipoprotein
10-2181991
KR
Nov 17, 2020
Status
Nano-perforator and pharmaceutical composition comprising the same for preventing or treating viral infection
10-2393872
KR
Apr 28, 2022
Status
Antiviral peptide from M2 protein and the use thereof
10-2417845
KR
Jul 1, 2022
Status
A viral receptor mimic compound bound with sialic acid compounds
10-2438721
KR
Aug 26, 2022
Status
Nanodisc with angiotensin converting enzyme 2 and its usage for disease from angiotensin converting enzyme 2 deficiency
10-2438720
KR
Aug 26, 2022
Status
Nanodisc with angiotensin converting enzyme 2 and its antiviral usage
11,541,100
US
Jan 3, 2023
Status
Pharmaceutical composition comprising nanoperforator for preventing or treating viral infectious diseases
10-2540331
KR
May 31, 2023
Status
Polymer nanodisc with angiotensin converting enzyme 2 and its antiviral usage
10-2540330
KR
May 31, 2023
Status
Nanodisc with phosphatidylethanolamine phospholipid
10-2556037
KR
Jul 11, 2023
Status
Pharmaceutical Composition for Preventing or Treating Viral Infection Comprising Polymer Nanodiscs
10-2610178
KR
Nov 30, 2023
Status
Nanodisc containing membrane scaffold protein fused with angiotensin converting enzyme 2
10-2613552
KR
Dec 8, 2023
Status
Tag protein for increasing solubility and thermal stability of target protein and fusion protein containing the same
11,957,697
US
Apr 16, 2024
Status
Viral receptor bound with sialic acid compounds
10-2675750
KR
Jun 12, 2024
Status
Nano-perforator having enhanced antiviral activity
10-2695050
KR
Aug 8, 2024
Status
Dual nanodisk with multiple nanodisks combined
10-2695049
KR
Aug 8, 2024
Status
Nanodisk with large membrane scffold protein
10-2702394
KR
Aug 29, 2024
Status
Nanodisc using dimer binding
10-2729353
KR
Nov 7, 2024
Status
Nanodisc containing membrane scaffold protein fused with Fc region of antibody
10-2737761
KR
Nov 28, 2024
Status
Nanodisc containing membrane scaffold protein fused with Fc region of antibody and viral receptor
10-2743940
KR
Dec 12, 2024
Status
Nanodisc with angiotensin converting enzyme 2 and Fc fragment and uses thereof
10-2743941
KR
Dec 12, 2024
Status
Nanodisc with virus receptor and Fc fragment and antiviral uses thereof
10-2817110
KR
May 30, 2025
Status
Nanodisc with antibody's Fab and Fc fragment
10-2879005
KR
Oct 27, 2025
Status
Nanodisc containing membrane scaffold protein fused with angiotensin converting enzyme 2 and and its antiviral use therof
12,459,978
US
Nov 4, 2025
Status
Tag protein for increasing water solubility and heat stability of target protein, and fusion protein comprising same